Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.160
-0.055 (-1.71%)
At close: Sep 10, 2026, 4:00 PM EDT
3.200
+0.040 (1.27%)
Pre-market: Sep 11, 2026, 4:14 AM EDT
Recursion Pharmaceuticals Market Cap
Recursion Pharmaceuticals has a market cap or net worth of $1.69 billion as of September 10, 2026. Its market cap has decreased by -17.50% in one year.
Market Cap
1.69B
Enterprise Value
1.22B
1-Year Change
-17.50%
Ranking
Category
Stock Price
$3.16
ChartMarket Cap Chart
Since April 16, 2021, Recursion Pharmaceuticals's market cap has decreased from $5.08B to $1.69B, a decrease of -66.61%. That is a compound annual growth rate of -18.37%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 10, 2026 | 1.69B | -20.39% |
| Dec 31, 2025 | 2.13B | -20.16% |
| Dec 31, 2024 | 2.67B | 24.83% |
| Dec 29, 2023 | 2.14B | 46.15% |
| Dec 30, 2022 | 1.46B | -49.51% |
| Dec 31, 2021 | 2.89B | -42.96% |
| Apr 16, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Lakefront Biotherapeutics NV | 1.76B |
| Braveheart Bio | 1.75B |
| Maravai LifeSciences Holdings | 1.75B |
| Kardigan | 1.75B |
| Immunocore Holdings | 1.73B |
| Taysha Gene Therapies | 1.68B |
| Syndax Pharmaceuticals | 1.68B |
| Intellia Therapeutics | 1.67B |